Clinical Trials

Adding a limited noncontrast pelvis CT with Agatston calcium scoring to evaluate and quantify calcified Peyronie plaques can increase the number of patients that qualify for collagenase Clostridium histolyticum (CCH) injection therapy compared with the qualitative assessment by penile duplex Doppler ultrasound (PDDU) and clinical exam.

The purpose of this study is to review the outcomes and patient characteristics for our institutional experience with the use of Xiaflex®.

Peyronie’s disease is a connective tissue disorder that causes fibrosis of the tunica albuginea. It is most commonly characterized by penile curvature while erect, penile pain, and erectile dysfunction. Collagenase clostridium histolyticum (XIAFLEX) is a injectable therapy that is FDA approved for the treatment of Peyronie’s disease. The goal of this study is to evaluate and report on treatment-associated outcomes in  patients with a diagnosis of Peyronie’s disease.

This clinical trial is designed to assess the safety, dosing, and preliminary efficacy of a novel penile traction device on correcting deformities relating to Peyronie's disease, a condition which results in penile curvature and length loss. The trial is designed as a randomized, placebo-controlled study with men randomized to receiving no therapy or penile traction therapy 30 minutes once, twice, or three times daily. The study will occur over a 3 month period, after which an open label phase for 3 months will be conducted. Final assessments for adverse effects will also be assessed at 9 months.

The purpose of this study is to provide comprehensive genetic profiling of Peyronie's Disease (PD) patients, discover candidate genes associated with the disease, and to compare the identified candidate genetic mutations/variations with familial and non-familial cases.

The purpose of this investigation is to develop and maintain a database for patients with PD +/- ED in the five years preceding the introduction of collagenase histolyticum (2008-2013) in comparison to the five years following Xiaflex FDA approval (2013-2018).